Drug intelligence / Profile preview

MK-0557 + sibutramine

Development stage: Phase 2
Lead developer: Merck
Modality: Small Molecules
Administration: Oral

Overview

This combination involves **MK-0557**, a potent and selective antagonist of the Neuropeptide Y5 receptor (NPY5R), and **sibutramine**, a centrally acting stimulant chemically related to amphetamines, used as an oral anorexiant. The combination was studied for its potential in treating obesity by enhancing weight loss efficacy. However, clinical trials showed that adding MK-0557 to sibutramine did not significantly increase weight loss compared to sibutramine alone[1][2].

Other names: mk-0557 + sibutraminesibutramine hydrochloride + MK-0557

Targets

NPY5R (Neuropeptide Y receptor type 5)NET (Norepinephrine Transporter)SERT (Sodium-dependent serotonin transporter)

Beyond the preview

Go deeper on MK-0557 + sibutramine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MK-0557 + sibutramine.